Top

Published in:

01-06-2007 | Review Article

The Role of NSAIDs in the Management of Postoperative Ophthalmic Inflammation

Author: Professor Joseph Colin

Published in: Drugs | Issue 9/2007

Abstract

Recent advances in cataract surgery, such as phacoemulsification, small-incision surgery and advances in foldable intraocular lenses, have resulted in the decrease of physical trauma associated with cataract surgery. The decrease in the physical surgical trauma decreases the release of prostaglandins, which are the main players in postoperative ocular inflammation. However, postoperative inflammation continues to be a cause of patient discomfort, delayed recovery and, in some cases, suboptimal visual results. Left untreated, this inflammation might interfere with patients’ rehabilitation and/or contribute to the development of other complications, such as cystoid macular oedema.

NSAIDs are commercially available, in topical or systemic formulations, for the prophylaxis and treatment of ocular conditions. Topically applied NSAIDs are commonly used in the management and prevention of non-infectious ocular inflammation and cystoid macular oedema following cataract surgery. They are also used in the management of pain following refractive surgery and in the treatment of allergic conjunctivitis. Despite their chemical heterogeneity, all NSAIDs share the similar therapeutic property of inhibiting the cyclo-oxygenase enzyme. The appeal of using NSAIDs in the treatment of ocular inflammation hinges on the complications associated with corticosteroids, the other commonly used therapy for ophthalmic inflammation.

Samiy N, Foster CS. The role of non-steroidal anti-inflammatory drugs in ocular inflammation. Int Ophthalmol Clin 1996; 36: 195–206PubMedCrossRef

Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin 2002; 42: 1–11PubMedCrossRef

Sawa M, Masuda K. Topical indomethacin in soft cataract aspiration. Jpn Ophthalmol 1976; 20: 514–9

Miyake K. Prevention of cystoid macular edema after lens extraction by topical indomethacin (II): a control study in bilateral extraction. Jpn Ophthalmol 1978; 22: 80–94

Miyake K, Sugiyama S, Norimatsu I. Prevention of cystoid macular edema after lens extraction by topical indomethacin (III): radioimmunoassay measurement of prostaglandins in the aqueous during and after lens extraction procedures. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1978; 209: 83–8PubMed

Miyake K. Prevention of cystoid macular edema after lens extraction by topical indomethacin (I): a preliminary report. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1977; 203: 81–8PubMed

Koay P. The emerging roles of non-steroidal anti-inflammatory agents in ophthalmology [comment in Br J Ophthalmol 1996; 80: 1117]. Br J Ophthalmol 1996; 80: 480–5PubMedCrossRef

Keates RH, McGowan KA. The effect of topical indomethacin ophthalmic solution in maintaining mydriasis during cataract surgery. Ann Ophthalmol 1984; 16: 1116–21PubMed

Keates RH, McGowan KA. Clinical trial of flurbiprofen to maintain papillary dilation during cataract surgery. Ann Ophthalmol 1984; 16: 919–21PubMed

10.

Stark WJ, Fagadu WR, Stewart RH, et al. Reduction of pupillary constriction during cataract surgery using suprofen. Arch Ophthalmol 1986; 104: 364–6PubMedCrossRef

11.

Arshinoff S, D’Addario D, Sadler C, et al. Use of topical non-steroidal anti-inflammatory drugs in excimer laser photorefractive keratectomy. J Cataract Refract Surg 1994; 20 Suppl.: 216–22PubMed

12.

Gwon A, Vaughan ER, Cheetham JK, et al. Ocufen (flurbiprofen) in the treatment of ocular pain after radial ker-atotomy. CLAO J 1994; 20: 131–8PubMed

13.

Gaynes BI, Fiscella R. Topical non-steroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug Safety 2002; 25: 233–50PubMedCrossRef

14.

Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. Surv Ophthalmol 1992; 36: 259–84PubMedCrossRef

15.

O’Brien TP. Emerging guidelines for use of NSAID therapy to optimized cataract surgery patient care. Curr Med Res Opin 2005; 21: 1131–7PubMedCrossRef

16.

Schalnus R. Topical non-steroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 2003; 217: 89–98PubMedCrossRef

17.

Perianin A, Roch-Arveiller M, Giroiung IP, et al. In vivo effects of indomethacin and flurbiprofen on the locomotion of neutro-phils elicited by immune and non-immune inflammation in the rat. Eur J Pharmacol 1985; 106: 327–33CrossRef

18.

Leonardi A, Busato F, Fregona I, et al. Anti-inflammatory and anti-allergic effects of ketorolac tromethamine in the conjunctival provocation model. Br J Ophthalmol 2000; 84: 1228–32PubMedCrossRef

19.

Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation 2003; 27: 281–91PubMedCrossRef

20.

Roberts CW. Pretreatment with topical diclofenac sodium to decrease postoperative inflammation. Ophthalmology 1996; 103: 636–9PubMed

21.

Flach AJ. Nonsteroidal anti-inflammatory drugs. In: Tasman W, editor. Duane’s foundations of clinical ophthalmology. Philadelphia (PA): Lippincott, 1994: 1–32

22.

Solomon KD, Cheetham JK, DeGryse R, et al. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology 2001; 108: 331–7PubMedCrossRef

23.

Lane SS, Modi SS, Lehmann RP, et al. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg 2007; 33: 53–8PubMedCrossRef

24.

Roberts CW, Brennan KM. A comparison of topical diclofenac with prednisolone for postcataract inflammation. Arch Ophthalmol 1995; 113: 725–7PubMedCrossRef

25.

El-Harazi SM, Ruiz RS, Feldman RM, et al. A randomized double-masked trial comparing ketorolac tromethamine 0.5%, diclofenac sodium 0.1%, and prednisolone acetate 1% in reducing post-phacoemulsification flare and cells. Ophthalmic Surg Lasers 1998; 29: 539–44PubMed

26.

Alpar JJ. Diclofenac sodium phosphate ophthalmic solution following cataract extraction [abstract]. 9th Congress of European Society of Ophthalmology; 1992 May; Brussels

27.

Simone JN, Pendelton RA, Jenkins JE. Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery. J Cataract Refract Surg 1999; 25: 699–704PubMedCrossRef

28.

Heier JS, Topping TM, Baumann W, et al. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology 2000; 107: 2034–9PubMedCrossRef

29.

Flach AJ. Discussion: ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology 2000; 107: 2039PubMedCrossRef

30.

Flach AJ, Graham J, Kruger LP, et al. Quantitative assessment of post-surgical breakdown of the blood-aqueous barrier following administration of ketorolac tromethamine solution: a double masked, paired comparison with vehicle-placebo solution study. Arch Ophthalmol 1988; 106: 344–7PubMedCrossRef

31.

Flach AJ, Lavelle CJ, Olander KW, et al. The effect of ketorolac 0.5% solution in reducing post-surgical inflammation following ECCE with IOL. Ophthalmology 1988; 95: 1279–84PubMed

32.

Snyder RW, Siekert RW, Schwiegerling J, et al. Acular as a single agent for use as an antimiotic and anti-inflammatory in cataract surgery. J Cataract Refract Surg 2000; 26: 1225–7PubMedCrossRef

33.

Hsu JK, Johnston WT, Read RW, et al. Histopathology of corneal melting associated with diclofenac use after refractive surgery. J Cataract Refract Surg 2003; 29: 250–6PubMedCrossRef

34.

Thomson Physician Desk Reference: PDR® Electronic Library™ [online]. Available from URL: http://www.pdr.net [Accessed 2007 Apr 24]

35.

Gamache DA, Graff G, Brady MT, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: assessment of anti-inflammatory efficacy. Inflammation 2000; 24: 357–70PubMedCrossRef

36.

McGee DH, Heaton JD, Gruebbel MM, et al. Ocular effects of nepafenac ophthalmic suspension in New Zealand white rabbits undergoing partial corneal incisions [abstract]. Invest Ophthalmol Vis Sci 2005; 46 Suppl.: 2648

37.

Walker LM, Rice RL, Heaton JD, et al. Ocular effects of nepafenac ophthalmic suspension following three months of topical ocular administration to cynomolgus monkeys [abstract]. Invest Ophthalmol Vis Sci 2005; 46 Suppl.: 2649CrossRef

38.

Heaton J, Hiddemen JW, Hackett RB, et al. Ocular effects of nepafenac ophthalmic suspension following six months of topical ocular administration to pigmented rabbits [abstract]. Invest Ophthalmol Vis Sci 2005; 46 Suppl.: 2650CrossRef

39.

Ke TL, Graff G, Spellman JM, et al. Nepafenac, a unique nonsteroidal pro-drug with potential utility in the treatment of trauma-induced ocular inflammation II: in vitro bioactivation and permeation of external ocular barriers. Inflammation 2000; 24: 371–84PubMedCrossRef

40.

Kern TS, Miller C, Du YP, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 2007; 56: 373–9PubMedCrossRef

41.

Takahashi K, Saishin Y, Saishin Y, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 409–15PubMedCrossRef

42.

Stewart WC, Stewart R, Maxwell WA, et al. Preoperative and postoperative clinical evaluation of nepafenac 0.1% ophthalmic suspension for postcataract inflammation. Paper presented at American Society of Cataract and Refractive Surgery; 2005 Apr 18, Washington, DC

43.

Nassaralla B, Szerenyi K, Wang XW, et al. Effect of diclofenac on corneal haze after photorefractive keratectomy in rabbits. Ophthalmology 1995; 102: 469–74PubMed

44.

Kraff MC, Sanders DR, McGuigan L, et al. Inhibition of blood-aqueous humor barrier breakdown with diclofenac: a fluorophotometric study. Arch Ophthalmol 1990; 108: 380–3PubMedCrossRef

45.

Vickers FF, McGuigan LJB, Ford C, et al. The effect of diclofenac sodium ophthalmic solution on the treatment of postoperative inflammation [abstract]. Annual meeting for the Association for Research in Vision and Ophthalmology; 1991 Apr 28–May 3; Sarasota, Florida. Invest Ophthalmol Vis Sci 1991; 32: 793

46.

Othenin-Girard P, Borruat X, Bovey E, et al. Association diclofenac-dexamethasone dans le traitement de l’inflammation postopératoire: étude prospective en double-insu. Klinische Monatsblatter Fúŕ Augenheilkunde 1992; 200: 362–6PubMedCrossRef

47.

Heier J, Cheetham JK, Degryse R, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial. Am J Ophthalmol 1999; 127: 253–9PubMedCrossRef

48.

Ostrov CS, Sirkin SR, Deutsh WE, et al. Ketorolac, prednisolone and dexamethasone for postoperative inflammation. Clin Ther 1997; 19: 259–72PubMedCrossRef

49.

Bucci FA, Evans RE, Amico LM. Comparison of ketorolac 0.5%, ketorolac 0.4%, and diclofenac 0.1% combined with prednisolone 0.1% on aqueous flare following cataract surgery [abstract]. Invest Ophthalmol Vis Sci 2005; 46 Suppl.: 789

50.

Flach AJ, Dolan BJ, Donahue ME, et al. Comparative effects of ketorolac 0.5% or diclofenac 0.1% ophthalmic solutions on inflammation after cataract surgery. Ophthalmology 1998; 105: 1775–9PubMedCrossRef

51.

Lu KL, Wee WR, Sakamoto T, et al. Comparison of in vitro antiproliferative effects of steroids and nonsteroidal antiin-flammatory drugs on human keratocytes. Cornea 1995; 15: 185–90CrossRef

52.

Diestelhorst M, Schmidl B, Konen W, et al. Efficacy and tolerance of diclofenac sodium 0.1%, flurbiprofen 0.03% and indomethacin 1.0% in controlling postoperative inflammation. J Cataract Refract Surg 1996; 22: 788–93PubMed

53.

Severin TD, Severin SL. Pseudophakic cystoid macular edema: a revised comparison of the incidence with intracapsular and extracapsular cataract extraction. Ophthal Surg 1988; 19: 116–8

54.

Mentes J, Erakgun T, Afrashi F, et al. Incidence of cystoid macular edema after uncomplicated phacoemulsification. Ophthalmologica 2003; 217: 408–12PubMedCrossRef

55.

Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol 2002; 47 Suppl. 1: S203–18PubMedCrossRef

56.

Rossetti L, Chaudhuri J, Dickersin K. Medical prophylaxis and treatment of cystoid macular edema after cataract surgery: the results of a meta-analysis. Ophthalmology 1998; 105: 397–405PubMedCrossRef

57.

Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc 1995; 96: 557–634

58.

Nelson ML, Martidis A. Managing cystoid macular edema after cataract surgery. Curr Opin Ophthalmol 2003; 14: 39–43PubMedCrossRef

59.

Heier JS. Preventing post-cataract extraction CME. Ophthalmol Manage 2004; October: 63–72

60.

Lindstrom RL, Dhaliwal DK, Dirks MS, et al. Clinical applications for NSAIDs in corneal disease and pre- and postoperative management. Ocul Surg News 2006 Feb 15; Suppl.: 1–26

61.

Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Cur Med Res Opin 2006; 22: 397–404CrossRef

62.

McColgin AZ, Raizman MB. Efficacy of topical voltaren in reducing the incidence of postoperative cystoid macular edema [abstract]. Invest Ophthalmol Vis Sci 1999; 40 Suppl.: 1529

63.

Rho DS. Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. J Cataract Refract Surg 2003; 29: 2378–84PubMedCrossRef

64.

Mishima H, Masuda K, Miyake K. The putative role of prostaglandins in cystoid macular edema. Prog Clin Biol Res 1989; 312: 251–64PubMed

65.

Miyake K, Masuda K, Shirato S, et al. Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicentered prospective trial. Jpn J Ophthalmol 2000; 44: 58–67PubMedCrossRef

66.

Flach AJ, Stegman RC, Graham J, et al. Prophylaxis of aphakic cystoid macular edema without corticosteroids: a paired-comparison, placebo-controlled double-masked study. Ophthalmology 1990; 97: 1253–8PubMed

67.

Flach AJ, Jampol LM, Weinberg D, et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol 1991; 112: 514–9PubMed

68.

Weisz JM, Bressler NM, Bressler SB, et al. Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction. Ophthalmology 1999; 106: 1656–9PubMedCrossRef

69.

Solomon KD. Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen-CME Study Group I. J Cataract Refract Surg 1995; 21: 73–81PubMed

70.

Ginsburg AP, Cheetham JK, DeGryse RE, et al. Effects of flurbiprofen and indomethacin on acute cystoid macular edema after cataract surgery: functional vision and contrast sensitivity. J Cataract Refract Surg 1995; 21: 82–92PubMed

71.

Miyake K, Sakamura S, Miura H. Long-term follow-up study on prevention of aphakic cystoid macular oedema by topical indomethacin. Br J Ophthalmol 1980; 64: 324–8PubMedCrossRef

72.

Ambache N, Kavanagh L, Whiting J. Effect of mechanical stimulation on rabbits’ eyes: release of active substance in anterior chamber perfusates. J Physiol 1965; 176: 378–408PubMed

73.

Anggard E. Samuelsson B. Smooth muscle stimulating lipids in sheep iris: the identification of prostaglandin F2 alpha. Pros-taglandins and related factors 21. Biochem Pharmacol 1964; 13: 281–3PubMedCrossRef

74.

Cole DF, Unger WG. Prostaglandins as mediator for the responses of the eye to trauma. Exp Eye Res 1973; 17: 357–68PubMedCrossRef

75.

Waitzman MB, King CD. Prostaglandin influences on intra ocular pressure and pupil size. Am J Physiol 1967; 212: 329–34PubMed

76.

Roberts CW. A comparison of diclofenac sodium to flurbiprofen for maintaining intraoperative mydriasis. Invest Ophthalmol Vis Sci 1993; 35: 1967

77.

Solomon KD, Turkalj JW, Whiteside SB, et al. Topical 0.5% ketorolac vs 0.03 flurbiprofen for inhibition of miosis during cataract surgery. Arch Ophthalmol 1997; 115: 1119–22PubMedCrossRef

78.

Roberts CW. Comparison of diclofenac sodium and flurbiprofen for inhibition of surgically induced miosis. J Cataract Refract Surg 1996; 22 Suppl. 1: 780–7PubMed

79.

Stewart R, Grosserode R, Cheetham JK, et al. Efficacy and safety profile of ketorolac 0.5% ophthalmic solution in the prevention of surgically induced miosis during cataract surgery. Clin Ther 1999; 21: 723–32PubMedCrossRef

80.

Cillino S, Casanova F, Cucco F, et al. Topical flurbiprofen in extracapsular cataract surgery: effect on pupillary diameter and iris fluoresin leakage. J Cataract Refract Surg 1993; 19: 622–5PubMed

81.

Colin J, Paquette B. Comparison of the analgesic efficacy of nepafenac ophthalmic suspension compared to diclofenac ophthalmic solution for ocular pain and photophobia after excimer laser surgery: a phase 2, randomized, double-masked trial. Clin Ther 2006; 28 (4): 527–36PubMedCrossRef

82.

Yee RW, the Ketorolac Radial Keratotomy Study Group. Analgesic efficacy and safety of nonpreserved ketorolac tromethamine ophthalmic solution following radial keratotomy. Am J Ophthalmol 1998; 125: 472–80PubMedCrossRef

83.

Solomon KD, Donnenfeld ED, Raizman M, et al. Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients. J Cataract Refract Surg 2004; 30: 1653–60PubMedCrossRef

84.

Price MO, Price FW. Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Cur Med Res Opin 2004; 20: 2015–9CrossRef

85.

Goyal R, Shankar J, Fone DL, et al. Randomized controlled trial of ketorolac in the management of corneal abrasions. Acta Ophthalmol Scand 2001; 79: 177–9PubMedCrossRef

86.

Kaiser PK, Pineda R, Corneal abrasion patching study group. A study of topical nonsteroidal anti-inflammatory drops and no pressure patching in the treatment of corneal abrasions. Ophthalmology 1997; 104: 1353–9PubMed

87.

Sher NA, Frantz JM, Talley A, et al. Topical diclofenac in the treatment of ocular pain after excimer photorefractive keratectomy. Refract Cornea Surg 1993; 9: 425–36

88.

Eiferman RA, Hoffman RS, Sher NA. Topical diclofenac reduces pain following photorefractive keratectomy. Arch Ophthalmol 1993; 111: 1022PubMedCrossRef

89.

Szerenyi K, Sorken K, Garbus JJ, et al. Decrease in normal human corneal sensitivity with topical diclofenac sodium. Am J Ophthalmol 1994; 118: 312–5PubMed

90.

Donshik PC, Pearlman D, Pinnas J, et al. Efficacy and safety of ketorolac tromethamine 0.5% and levocabastin 0.05%: a multicenter comparison in patients with seasonal allergic conjunctivitis. Adv Ther 2000; 17: 94–102PubMedCrossRef

91.

Laibovitz RA, Koester J, Schaich L, et al. Safety and efficacy of diclofenac sodium 0.1% ophthalmic solution in acute seasonal allergic conjunctivitis. J Ocul Pharmacol Ther 1995; 11: 361–8PubMedCrossRef

92.

Wood TS, Stewart RH, Bowman RW, et al. Suprofen treatment of contact ICNS-associated giant papillary conjunctivitis. Ophthalmology 1988; 95: 822–6PubMed

93.

Tauber J, Raizman MB, Ostrov CS, et al. A multi-center comparison of the ocular safety and efficacy of diclofenac sodium 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. J Ocul Pharmacol Therp 1998; 14: 137–45CrossRef

94.

Ciprandi G, Buscaglia S, Cerqueti MP, et al. Topical anti-inflammatory drugs in the treatment of allergic pollinosic conjunctivities: a comparative double-blind study. J Invest Allergol Clin Immunol 1992; 2 (5): 248–52

95.

Frucht-Perry J, Siganos CS, Solomon A, et al. Topical indomethacin solution versus dexamethasone solution for treatment of inflamed pterygium and pinguecula: a prospective randomized clinical study. Am J Ophthalmol 1999; 127: 148–52CrossRef

96.

Goethals M, Missotten L. Efficacy and safety of indomethacin 0.1% versus flurbiprofen 0.03% eye drops in inflammation after argon laser trabeculoplasty. Doc Ophthalmol 1994; 85: 287–93PubMedCrossRef

97.

Kent AR, Dubiner HB, Whitaker R, et al. The safety and efficacy of diclofenac 0.1% versus prednisolone acetate 1% following trabeculectomy with adjunctive mitomycin-C. Opthalmic Surg Lasers 1998; 29: 562–9

98.

Apt L, Voo I, Isenberg SJ. A randomized clinical trial of the non-steroidal eye drop diclofenac after strabismus surgery. Ophthalmology 1998; 105: 1449–52CrossRef

99.

Rajpal RK, Cooperman BB. Analgesic efficacy and safety of ketorolac after photorefractive keratectomy. J Refract Surg 1999; 15: 661–7PubMed

100.

Costagliola C, Parmeggiani F, Antinozzi PP, et al. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timlol and 0.005% latanoprost in primary open-angle glaucoma patients. Exp Eye Res 2005; 81: 610–5PubMedCrossRef

101.

Koevary SB. Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond. Curr Drug Metabol 2003; 4: 213–22CrossRef

102.

Song Q, McCollum GW, Macrorie-Fairweather R, et al. Nepafenac metabolite, amfenac, inhibits VEGF induced phosphorylation of ERK in human retinal microvascular endothelial cells [abstract]. Invest Ophthalmol Vis Sci 2005; 46 Suppl.: 4204

103.

Souza Filho JP, Correa ZM, Marshall JCA, et al. The effect of a selective cyclooxygenase-2 (COX-2) inhibitor on the prolifer-ative rate of retinoblastoma cell lines [abstract]. Invest Ophthalmol Vis Sci 2005; 46 Suppl.: 3418

104.

Caissie AL, Marshall JCA, Odashiro AN, et al. The cyclooxygenase-2 inhibitor nepafenac improves the function of macrophages suppressed by uveal melanoma conditioned medium [abstract]. Invest Ophthalmol Vis Sci 2005; 46 Suppl.: 3407

105.

Nguyen KD, Lee DA. Effects of steroids and nonsteroidal antiinflammatory agents on human ocular fibroblast. Invest Ophthalmol Vis Sci 1992; 33: 2693–701PubMed

106.

Nguyen KD, Lee DA. In vitro evaluation of antiproliferative potential of topical cyclo-oxygenase inhibitors in human Tenon’s fibroblasts. Exp Eye Res 1993; 57: 97–105PubMedCrossRef

107.

Sharir M Exacerbation of asthma by topical diclofenac. Arch Opthalmol 1997; 115:294–5CrossRef

108.

Polachek J, Shvartzman P. Acute bronchial asthma associated with the administration of indomethacin. Isr J Med Sci 1996; 32: 1107–9PubMed

109.

Sheehan GJ, Kutzner MR, Chin WD. Acute asthma attack due to ophthalmic indomethacin. Ann Intern Med 1989; 111: 337–8PubMed

110.

Gills JP. Voltaren associated with medication keratitis [letter]. J Cataract Refract Surg 1994; 20: 110PubMed

111.

Sher NA, Krueger RR, Teal R, et al. Role of topical corticoste-roids and nonsteroidal anti-inflammatory drugs in the etiology of stromal infiltrates after excimer photorefractive keratectomy. J Refract Corneal Surg 1994; 10: 587–8PubMed

112.

Shimazaki J, Saito H, Yang HY, et al. Persistent epithelial defect following penetrating keratoplasty: an adverse effect of diclofenac eye drops. Cornea 1995; 14: 623–7PubMed

113.

Guidera AC, Luchs JI, Udell IJ. Keratitis, Ulcération, and perforation associated with topical non-steroidal anti-inflammatory drugs. Ophthalmology 2001; 108: 936–44PubMedCrossRef

114.

Congdon NG, Schein OD, van Kulajta P, et al. Corneal complications associated with topical ophthalmic use of nonsteroidal anti-inflammatory drugs. J Cataract Refract Surg 2001; 27: 622–31PubMedCrossRef

115.

O’Brien TP, Li QJ, Sauerburger F, et al. The role of matrix metalloproteinases in ulcerative keratolysis associated with perioperative diclofenac use. Ophthalmology 2001; 108: 656–9PubMedCrossRef

116.

Reviglio VE, Rana TS, Li QJ, et al. Effects of topical nonsteroidal antiinflammatory drugs on the expression of matrix metalloproteinases in the cornea. J Cataract Refract Surg 2003; 29: 989–97PubMedCrossRef

117.

Asai T, Nakagami T, Mochizuki M, et al. Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug. Cornea 2006; 25: 224–7PubMedCrossRef

118.

Mian SI, Gupta A, Pineda R II. Corneal ulceration and perforation with ketorolac tromethamine (Acular®) use after PRK. Cornea 2006; 25: 232–4PubMedCrossRef

Title: The Role of NSAIDs in the Management of Postoperative Ophthalmic Inflammation
Author: Professor Joseph Colin
Publication date: 01-06-2007
Publisher: Springer International Publishing
Published in: Drugs / Issue 9/2007
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200767090-00004

2024 ASCO Annual Meeting

Springer Medicine

The Role of NSAIDs in the Management of Postoperative Ophthalmic Inflammation

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2007

Advanced Renal Cell Carcinoma

Imidapril

HER2-Positive Breast Cancer

Glucocorticoids in the Prevention of Restenosis After Coronary Angioplasty

Dihydropyridine Calcium Channel Antagonists in the Management of Hypertension

Antiepileptic Drugs in the Treatment of Neuropathic Pain